Bottom line
What is LGVAX's expense ratio?
LGVAX's expense ratio is 1.01%, or about $101 a year on every $10,000 invested. That is more expensive than 68% of large value funds we track (median 0.81%). This share class also charges a front-end sales load of up to 5.5%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Feb 24, 2026
LGVAX fee table
| Net expense ratio | 1.01% |
|---|---|
| Gross expense ratio | 1.04% |
| Management fee | 0.64% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.15% |
| Fee waiver / reimbursement | -0.03% |
| Max front-end sales load | 5.5% |
| Max deferred sales charge | 0% |
Source: Fund prospectus fee table, filed Feb 24, 2026
What LGVAX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| LGVAX | $647 | $859 | $1,089 | $1,749 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.01% expense ratio costs roughly $55,900 in lost growth, versus about $45,600 for the median large value fund (0.81%).